In this month’s issue of Drug Development & Delivery our research team Charlotte Dunne, PhD, Katrin Radloff, PhD and Leonidas Gkionis, PhD describe Pantherna’s mRNA and LNP technology platforms.
Pantherna has established the “3-flavour” PTXΔLNP platform for mRNA formulation with precision fine tuning to produce cell-selective LNPs in addition to high batch-to-batch consistency, robust stability, and improved delivery efficiency.

Read more here to learn about local and systemic therapeutic opportunities for the PTXΔLNP® Platform in combination with Pantherna’s sister technology platform PTXmRNA®.

Contact for additional information:  
Dr. Ansgar Santel, Head of Translational Research and Alliance Management  

T: +49(0)3302-202 240-0  
E-Mail: a.santel@pantherna-therapeutics.com